Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1

Status

Recruiting 2Active not recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

NET 6Gastrointestinal 6Endocrine 6CNS 1

Conditions

Neuroendocrine Tumors 21Meningioma 6Gastro-enteropancreatic neuroendocrine tumor 6Pheochromocytoma 3Paraganglioma 3Prostatic Neoplasms 2Neuroblastoma 2Medulloblastoma 2Glioma 2Glioblastoma 2Ependymoma 2Carcinoma, Merkel Cell 2Adenoma, Islet Cell 2Somatostatin Receptor-positive Neuroendocrine Tumor 1Sarcoma, Synovial 1Recurrence 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Hypertension 1Extensive Stage Small Cell Lung Cancer 1Esthesioneuroblastoma, Olfactory 1Disease Progression 1Digestive System Neuroendocrine Tumor G1 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma 1

Interventions

lutetium Lu 177 dotatate 6Octreotide 3pasireotide 2lanreotide 2gallium Ga 68 dotatate 2copper dotatate CU-64 2amino-acid, glucose, and electrolyte solution 2Magnetic Resonance Spectroscopy 2Lutetium-177 2Lutetium 2Ga(III)-DOTATOC 2Everolimus 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2zimberelimab 1irinotecan sucrosofate 1abemaciclib 1X-Rays 1Temozolomide 1Sunitinib 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1Radiosurgery 1PM 01183 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Ipilimumab 1Folfox protocol 1Fluorouracil 1E-7386 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Gastro-enteropancreatic neuroendocrine tumor × lutetium Lu 177 dotatate × 1 year × Clear all
NCT04727723 2026-05-04

REAL-LU

Novartis

Completed
164 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT07150546 2026-03-02

Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.

Emory University

Phase 1 Recruiting
15 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT03972488 2026-01-21

NETTER-2

Advanced Accelerator Applications

Phase 3 Active not recruiting
226 enrolled 14 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT05987176 2026-01-14

NELMAS

Imperial College London

Phase 2 Terminated
1 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT04609592 2025-09-09

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Stanford University

Phase 1 Recruiting
10 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡